First-in-human trial evaluates safety and pharmacokinetics of AZP2006 across single and multiple doses, highlighting a potential therapy to stabilize progranulin and reduce tau aggregation.
Alzheimer's disease (AD) and progressive supranuclear palsy (PSP) are major neurodegenerative conditions with tau pathology in common but distinct symptoms-AD involves cognitive decline while PSP affects balance and eye movement. Progranulin (PGRN) is a growth factor implicated in neurodegenerative diseases, including AD and PSP. AZP2006, a synthetic compound, targets tauopathies by stabilizing PGRN levels and reducing tau aggregation and neuroinflammation.
No takes yet. Share an insight, caveat, or question.
Verwaerde et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: